Navigation Links
Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
Date:2/12/2008

bavituximab in combination with chemotherapy. The first bavituximab breast cancer trial is now underway and the two other trials are expected to begin soon. Bavituximab is in clinical trials in the U.S. in patients with advanced solid tumors and in patients co-infected with HCV and HIV.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the company will experience delays or difficulties in enrolling patients in the study, the risk that the standard docetaxel response rate will not be improved as a result of the combination therapy, and the risk that the results from this trial will not be consistent with the results of prior trials or preclinical studies. It is important to note that the company's actual results could differ materially from th
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
2. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
3. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
6. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
9. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
11. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... IL (PRWEB) , ... June 30, 2015 , ... ... effective August 14. She has accepted the position of vice president of instruction ... August 17. , “I greatly appreciated the opportunity to lead SIUE during ...
(Date:6/30/2015)... Tampa, Florida (PRWEB) , ... June 30, 2015 ... ... medical cannabis digital media company, launched “Cannavoices,” an unprecedented digital video and ... the largest but also the most dynamic collection of legal medical cannabis stories ...
(Date:6/29/2015)...   Pharnext SAS today announced that data related ... of Charcot-Marie-Tooth Type 1A (CMT1A), is being presented in four ... Society (PNS) Biennial Meeting at the Quebec Congress Center in ... July 2, 2015. At Poster Viewing Session 4, ... to 7p.m. EDT: Poster 23: "A Meta-Analysis ...
(Date:6/29/2015)... ... June 29, 2015 , ... The global microfluidics ... the forecast period (2015 to 2020). The market is mainly driven by the ... funding for R&D. However, lack of adequate healthcare and research infrastructure in emerging ...
Breaking Biology Technology:SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 2SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 3Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 3Pharnext's PXT-3003 Featured in Multiple Presentations at 2015 Peripheral Nerve Society Biennial Meeting 2Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 2Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 3Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 4Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 5
... with Pfizer,s recently ... MALIBU, Calif., Nov. 15 Pathway Diagnostics announces,that the ... Patent,number 7,294,458 (the ,458 patent) entitled "Analysis of HIV-1 ... Diagnostics,has licensed the ,458 patent (with rights to sub-license) ...
... At a meeting of the,Board of ... ), held today, a dividend of ... outstanding shares of Preferred Stock was,declared ... stockholders of record at the close,of ...
... George Abercrombie, Pfizer R&D Head Martin,Mackay, HHS Deputy Secretary ... Headline Agenda at FDA/CMS Summit 2007, WASHINGTON, Nov. ... for drug approvals. Unfortunately for the biopharma sector and,investors, ... is on track,to grant marketing approval to 18 or ...
Cached Biology Technology:Pathway Diagnostics Announces Patent Issuance for the Diagnostic Measurement of HIV Tropism for the Initiation or Modification of HIV Therapy 2So Long, Old Friend: The End of the Blockbuster Drug Era? What 2008 Holds for Bringing Drugs to Market 2So Long, Old Friend: The End of the Blockbuster Drug Era? What 2008 Holds for Bringing Drugs to Market 3
(Date:6/23/2015)... , June 23, 2015  Crossmatch™, ... and authentication solutions, today announced enhanced functionality of ... authentication solution.  The enhancements build on the ... the DigitalPersona Altus platform and provide expanded ... In today,s environment of increasing ...
(Date:6/18/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") ... market announces that its Wocket® smart wallet will be the ... scheduled to air on WABC Radio (am770) in ... The broadcast air- time for the extensive one ... Inc.,s CEO Gino Pereira will be discussing its ...
(Date:6/17/2015)... Germany , June 17, 2015 ... QIA) today launched new Investigator ® STR assay kits ... the United States . The new genetic fingerprint ... genomic markers (short tandem repeats or STRs) for DNA matching. ... the quality of DNA in each sample, a novel QIAGEN ...
Breaking Biology News(10 mins):Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5
... an important role in various addictions, such as alcoholism ... is due, in part, to genetic factors, reveals new ... is a neuropeptide that both activates the brain,s reward ... are hungry, levels of ghrelin increase, activating the brain,s ...
... Alberta-led research team has determined that the mountain pine beetle ... possibility for an infestation that could stretch across the Prairies ... of U of A tree biologists and geneticists discovered that, ... Columbia, it successfully jumped species from its main host, the ...
... in the United States in late 2004, many producers feared ... of the world. In response to this threat, researchers have ... fungus, and a recent report in Crop Science ... to determine which of the soybean germplasm accessions were resistant ...
Cached Biology News:Genetic changes behind sweet tooth 2Soybean germplasm evaluations give US a head start against soybean rust pathogen 2Soybean germplasm evaluations give US a head start against soybean rust pathogen 3
... EnVision™ G|2 Doublestain System is ... generation visualization kit. The kit is ... the simultaneous detection of two different ... is compatible with suitably diluted rabbit ...
Liquid. PBS containing 10 mM NaN 3 . AVOID FREEZE/THAW CYCLES. Recognizes α1, 2, 3, 5, 6 and 7 subunits of 20S proteasome. ...
AVOID FREEZE/THAW CYCLES. Recognizes the UCP-2 protein....
Mouse monoclonal antibody to Lats2....
Biology Products: